Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Ulocuplumab

🥰Excellent
Catalog No. T76794Cas No. 1375830-34-4
Alias MDX 1338, BMS 936564

Ulocuplumab (BMS-936564) is a fully human anti-CXCR4 IgG4 antibody.Ulocplumab exhibits antitumor activity in acute myeloid leukemia (AML), non-Hodgkin's lymphoma (NHL), and multiple myeloma transplantation models.Ulocplumab inhibits the migration of chronic lymphocytic leukemia (CLL) cells under CXCR4 activation, induces apoptosis, and inhibits the growth and migration of cancer cells. Ulocplumab inhibits CXCL12-mediated chronic lymphocytic leukemia (CLL) cell migration in response to CXCR4 activation and induces apoptosis.)

Ulocuplumab

Ulocuplumab

🥰Excellent
Purity: 96.2% (SEC-HPLC)
Catalog No. T76794Alias MDX 1338, BMS 936564Cas No. 1375830-34-4
Ulocuplumab (BMS-936564) is a fully human anti-CXCR4 IgG4 antibody.Ulocplumab exhibits antitumor activity in acute myeloid leukemia (AML), non-Hodgkin's lymphoma (NHL), and multiple myeloma transplantation models.Ulocplumab inhibits the migration of chronic lymphocytic leukemia (CLL) cells under CXCR4 activation, induces apoptosis, and inhibits the growth and migration of cancer cells. Ulocplumab inhibits CXCL12-mediated chronic lymphocytic leukemia (CLL) cell migration in response to CXCR4 activation and induces apoptosis.)
Pack SizePriceAvailabilityQuantity
1 mg$247In Stock
5 mg$708In Stock
10 mg$987In Stock
Bulk & Custom
Add to Cart
Questions
View More
Select Batch
Concentration:2.29 mg/mL
Purity:96.2% (SEC-HPLC)
Contact us for more batch information
Resource Download
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Introduction

Bioactivity
Description
Ulocuplumab (BMS-936564) is a fully human anti-CXCR4 IgG4 antibody.Ulocplumab exhibits antitumor activity in acute myeloid leukemia (AML), non-Hodgkin's lymphoma (NHL), and multiple myeloma transplantation models.Ulocplumab inhibits the migration of chronic lymphocytic leukemia (CLL) cells under CXCR4 activation, induces apoptosis, and inhibits the growth and migration of cancer cells. Ulocplumab inhibits CXCL12-mediated chronic lymphocytic leukemia (CLL) cell migration in response to CXCR4 activation and induces apoptosis.)
Targets&IC50
Ramos cells:10 nM
In vitro
Ulocuplumab (0-100 μM; 48 h) lacks antibody-dependent cell-mediated cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) activity. However, it induces CXCR4-binding-mediated apoptosis in Ramos cells and CLL or cancer cell lines. It also demonstrates pro-apoptotic effects in primary leukemia cells from CLL patients [1].
Ulocuplumab (0.2 μM, 2 μM; 15 s) inhibits F-actin polymerization, reduces peak responses to CXCL12, and (20 nM-2 μM; 1 h) additionally inhibits cell migration [1].
At a concentration of 200 nM for 6 hours, Ulocuplumab induces programmed cell death (PCD) independently of caspases [1].
Ulocuplumab (10 μg/mL; 4 h) induces cell death in CLL cells by generating reactive oxygen species (ROS) [1].
Ulocuplumab inhibits CXCL12-induced calcium flux, with an EC50 of 10 nM in Ramos cells [2].
In vivo
Ulocuplumab (3-30 mg/kg; intraperitoneal injection; 5 doses over 3-4 days; a total of 65 days) inhibits tumor growth in a murine multiple myeloma xenograft model, including tumor models with Ramos B cells, HL-60 cells, MOLP-8 cells, Nomo-1 cells, and JJN-3R cells [1].
AliasMDX 1338, BMS 936564
Chemical Properties
Molecular Weight146.23 kDa
Cas No.1375830-34-4
Storage & Solubility Information
Storagestore at low temperature | store at -20°C | Shipping with blue ice.

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy Ulocuplumab | purchase Ulocuplumab | Ulocuplumab cost | order Ulocuplumab | Ulocuplumab in vivo | Ulocuplumab in vitro | Ulocuplumab molecular weight